MDxHealth Signs Worldwide Development & Commercialization Agreement With Merck KGaA for MGMT Diagnostic Test

Regulatory News MDxHealth SA NYSE Euronext MDXH a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment announced…
Read the full story: Bioportfolio Biomarker News